{"id":"W2593142478","doi":"10.1158/1538-7445.sabcs16-p2-08-02","title":"Abstract P2-08-02: Progression-free survival results in patient subgroups from a Phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Anastrozole; Fulvestrant; Medicine; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Metastatic breast cancer; Breast cancer; Progression-free survival; Randomized controlled trial; Cancer; Estrogen receptor; Tamoxifen; Confidence interval; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004026465,0.00192414,0.002564856,0.0005083961,0.0006286923,0.001181187,0.0009376634,0.001650026,0.00796595],"category_scores_gemma":[0.002907007,0.0005003628,0.002749445,0.0005566772,0.001211718,0.001055543,0.000540642,0.003258456,0.0006883072],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001049582,"about_ca_system_score_gemma":0.002062408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001074908,"about_ca_topic_score_gemma":0.002781154,"domain_scores_codex":[0.9980196,0.001358546,0.0001194735,0.0002177654,0.00009024294,0.0001943362],"domain_scores_gemma":[0.9980826,0.0006167496,0.0004001402,0.0001839265,0.0001471936,0.0005694004],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9874794,0.00295583,0.0008066907,0.0001320452,0.000633337,0.00002604828,0.00002420455,0.0002806295,0.001839204,0.00004259235,0.0006827516,0.005097302],"study_design_scores_gemma":[0.9041033,0.08874457,0.004263242,0.00002396515,0.0008859163,0.00003953857,0.00003223126,0.0005557382,0.0004754942,0.0001944487,0.0006622326,0.00001930889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882208,0.002171787,0.0004588547,0.0008577159,0.0002507549,0.003784077,0.002514392,0.00009034403,0.001651149],"genre_scores_gemma":[0.9876917,0.0006059944,0.0009904747,0.001231515,0.0003207692,0.004765761,0.002847224,0.00002285844,0.00152369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00796595,"threshold_uncertainty_score":0.02664876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04892518589419236,"score_gpt":0.4243854917778676,"score_spread":0.3754603058836752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}